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Substantial evidence indicates that several common viruses are clearly or probable causal factors in the etiology of specific malignancies. These
viruses either normally establish latency or can become persistent infections. Oncogenesis is probably linked to an enhanced level of viral activation
in the infected host, reflecting heavy viral dose or compromised immune control. The major virus-malignancy systems include hepatitis B virus
(HBV), hepatitis C virus (HCV), and hepatocellular carcinoma; human lymphotropic virus-type 1 (HTLV-1) and adult T-cell leukemia/lymphoma (ATL);
Epstein-Barr virus (EBV) and endemic Burkitt's lymphoma, nasopharyngeal carcinoma, and Hodgkin's disease; and human papilloma virus (HPV) and
cervical cancer. Of these, a vaccine is available only for HBV. These malignancies tend to occur in early to mid-life and account for a substantial
amount of morbidity and person-years lost. They are also likely to occur as "opportunistic malignancies" among individuals infected with human
immunodeficiency virus type-1, particularly among those who experience prolonged survival. - Environ Health Perspect 103(Suppl 8):259-261 (1995)
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Introduction
Substantial evidence indicates that several
common human viral infections clearly or
probably are factors in the etiology of
specific malignancies. The evidence for
these relationships is aided by the revolu-
tion in molecular biology, resulting in more
sensitive and specific assays for detection of
viral genes or gene products. The evidence
regarding causality is strongest when viral
biomarkers are consistently identified in
tumor tissue, particularly when clonality of
viral sequences can be established. Identifi-
cation of consistent alterations in the pat-
tern ofantibody response to viral antigens
is also a useful strategy. Antibodies tend not
to provide immunologic control to these
viral infections; rather, in many cases ele-
vated antibodies reflect a heavy viral or
proviral load (1).
These viruses include the hepatitis
viruses hepatitis B virus (HBV) and hepa-
titis C virus (HCV), human T-lympho-
tropic virus-type 1 (HTLV-1), Epstein-Barr
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virus (EBV), and some human papilloma
virus (HPV) genotypes that normally infect
the genital tract. These viruses normally
establish latency, or in the case of the
hepatitis viruses, become persistent infec-
tions under certain circumstances. Risk of
malignancy generally is related to some
compromise to host control of the infec-
tion. This could be due to an early or
severe primary infection or to a disruption
of immune function such as that seen in
human immunodeficiency virus-type 1
(HIV-1) infection. These malignancies
generally are rare outcomes ofthese infec-
tions, which indicates that most individuals
control these infections adequately.
The major virus-associated malignan-
cies are listed in Table 1. These include a
surprisingly diverse set of malignancies.
The mechanisms involved are not under-
stood. The simplest model ofan insertion
ofviral sequences into a common, critical
region ofthe host genome does not charac-
terize any ofthese human virus-associated
malignancies. Viral transactivation ofhost
oncogenes is the most probable mechanism
Table 1. The major virus-associated malignancies in
humans.
Malignancy Virus Virus family
Hepatocellular HBV Hepadnaviridae
carcinoma
Hepatocellular HCV Flaviviridae
carcinoma
AdultT-cell HTLV-1 Retroviridae
lymphoma/leukemia
Burkitt's lymphoma EBV Herpesviridae
Nasopharnygeal EBV Herpesviridae
carcinoma
Hodgkin's disease EBV Herpesviridae
Cervical cancer HPV-16, 18 Papovaviridae
31,45
in HTLV-1 (2). Several of these viruses
have gene products that actually interact
with suppressor genes, as is true for HPVs
16 and 18 (3). There may be less direct
mechanisms ofviral activity that increase
the likelihood of chromosomal transloca-
tion leading to up-regulation ofoncogenes
such as in Burkitt's lymphoma (4). Alter-
natively, there may be a promoterlike
mechanism by a recurrent induction ofcell
division, as seen in chronic HBV infection
and hepatocellular carcinoma (5).
In general, these malignancies occur
relatively early in life, typically peaking in
middle-age or earlier, as shown in Figure 1.
Such a curve indicates that risk is associ-
ated with infection in early life (10). This
observation also implies that viral-associ-
ated malignancies have a disproportionate
public health impact via years of life and
workingyears lost.
The causal relationships between both
HBV and HCV and hepatocellular carci-
noma is established through substantial
epidemiologic evidence (5). Both appear to
act via chronic replication in the liver by
causing cell death and subsequent regenera-
tion. For HBV, the risk factor strongly
associated with hepatocellular carcinoma is
the seroprevalence ofhepatitis B surface
antigen (HBsAg), which is evidence of
chronic viremia and occurs primarily under
circumstances of perinatal infection, par-
ticularly among men. HBV-associated liver
cancer almost always occurs in the presence
of cirrhosis. The evidence for causality is
the extremely strong association between
the HBsAg and the evidence ofintegrated
clonal HBV in tumor and surrounding tis-
sue. After extensive review of the data, an
International Agency for Research on
Cancer (IARC) Working Group recently
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Figure 1. Age-specific incidence rates for the major
virus-associated malignancies. Adult T-cell leukemia/
lymphoma (ATL): males, 1986 to 1987, Kyushu, Japan
(6); Burkitt's lymphoma: males, 1961 to 1975, West
Nile District, Uganda (7); Hodgkin's disease: males,
1986 to 1990, SEER Program (8); nasopharynx: males,
1983 to 1987, Chinese, Singapore (9).
concluded that HBV is a Group I human
carcinogen. Intervention by immunization
ofhigh-risk infants, which is now under
way in many endemic populations, is likely
to prevent the disease among future
generations. Treatment of chronic HBV
infection with a combination ofinterferons
has been found to be effective in convert-
ing patients from an antigenemia to an
antibody-positive state (5).
In contrast to the long history of
research on HBV, HCV has only been
identified since 1989 (5). The virus itself
has not even been visualized, although it
has been cloned, and its natural history is
largely undefined. Serologic and genome
probes have been developed using cloned
fragments ofthe virus. Based on these bio-
markers, the epidemiologic evidence link-
ing HCV infection to hepatocellular
carcinoma is so strong that it also has been
classified as a Class I human carcinogen by
IARC. These assays are being used to
screen the blood supply, which should
reduce the incidence of HCV infection.
There is some evidence that a proportion
of HCV carriers who have evidence of
chronic hepatitis can clear the infection
with treatment by interferon (5).
The association between HTLV-1 and
adult T-cell leukemia/lymphoma (ATL)
also is firmly established (11). Unlike the
other oncogenic viruses found throughout
theworld, HTLV-1 is highlygeographically
restricted, being found primarily in south-
ern Japan, the Caribbean, west and central
Africa, and the South Pacific islands.
Evidence for causality includes the mono-
clonal integration ofviral genome in almost
all cases ofATL in carriers. No oncogene
activation is seen, but it is thought that part
of the oncogenic process involves the up-
regulation ofthe transactivating taxprotein
ofthe virus. Like HBV and liver cancer, the
risk factors for HTLV-1-associated malig-
nancy appear to be perinatal infection, high
viral load, and being male sex (2).
Since perinatal transmission ofHTLV-1
occurs primarily through infected lympho-
cytes in breast milk, screening mothers in
endemic populations prior to delivery and
discouraging breast-feeding is substantially
reducing the occurrence ofperinatal trans-
mission. Breast-feeding for less than 6
months appears to be equivalent to total
cessation in reducing infection, and consen-
sus on public health policies should be
sought. The risk associated with sexually
acquired infection has not been defined (2).
There is a substantial amount of evi-
dence that EBV is a causal factor in three
quite different malignancies. These include
Burkitt's lymphoma, nasopharyngeal carci-
noma, and Hodgkin's disease. In each case,
there are consistent serologic and molecu-
lar patterns of EBV fingerprints associated
with the specific malignancy (1,4). These
are summarized in Table 2. The potential
for developing a vaccine against EBV
continues to be an important issue.
The evolution ofour understanding of
the role ofEBV in endemic Burkitt's lym-
phoma led to three milestones that serve as
paradigms for virus-associated malignan-
cies. These include identification and isola-
tion ofthe virus itselffrom Burkitt's tumor;
use of the prospective seroepidemiologic
study to identify the antibody pattern,
which can distinguish future cases of the
disease; and discovery of the link between
the characteristic chromosome translocation
and the activation ofc-myc(4).
Clonal EBV episomes are found in
essentially all cases of endemic Burkitt's
lymphoma, which is traditionally defined
as occurring in tropical areas among chil-
dren with holoendemic malaria. It appears
that a combination ofearly EBV infection
with the constant mitogenic stimulation of
malaria on infected lymphocytes inducing
gene rearrangements for immunoglobulin
specificity can set off the chain of events
leading to the activation of c-myc. A sec-
ondary event in a suppressor gene probably
also occurs. EBV is also found in about
20% of cases of nonendemic Burkitt's
lymphoma. It is important to note that
EBV-negative tumors share the same chro-
mosomal translocation. This illustrates the
general principle that there can be multiple
causal pathways to the same syndrome and,
in this case, the same genetic lesions.
The prospective study undertaken in
Uganda in the early 1970s, which involved
serologic testing of42,000 children, led to
identification of 14 subsequent cases (12).
Antibody analyses ofspecimens from these
cases and matched controls determined
that although essentially all the children
were infected with EBV at initial screen,
those cases that resulted in cancer had
significantly higher titers against the viral
Table 2. The pattern of Ebstein-Barr virus biomarkers in associated malignancies.
Marker Burkitt's lymphoma Nasopharyngeal carcinoma Hodgkin's disease
Antibody
VCA
IgG 1K1 1 1T
IgA T1 T
IgM 1
EBNA 11
Earlyantigen
Diffuse - T (IgA) T
Restricted Ta +
Molecular
Clonality Yes Yes Yes
Latent phenotype EBNA-1 only EBNA2-, LMP1+ EBNA2-, LMP1+
Predictive of recurrence following treatment.
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capsid antigen (VCA). In addition, the
appearance ofan antibody to the restricted
form of the early antigen following treat-
ment indicated a relapse.
EBV is also clearly involved in the etiol-
ogy ofundifferentiated nasopharyngeal car-
cinoma, especially among persons of
southern Chinese origin (13). Again,
clonal episomal viral genome is found in
the tumor and a distinctive serologic pat-
tern is found at diagnosis, including the
presence of immunoglobulin A (IgA)
against the VCA. Relapse is heralded by
the reappearance or increase in IgA against
the VCA and the restricted form of the
early antigen. In affected tissue, EBV
expresses a unique latent phenotype that
differs from that seen in Burkitt's tumor. It
currently is not clear how other risk factors
for nasopharyngeal carcinoma such as
ingestion of salted foods relate to EBV in
the pathogenesis of this malignancy. In
terms of prevention in high risk popula-
tions, screening for the presence of IgA
has been used to detect early, treatable
cases (13).
EBV has been linked to Hodgkin's
disease by serology both following and
preceding diagnosis (4). Further, there is a
consistent association of young adult
Hodgkin's disease with risk factors that
implicate the role oflate primary infection
with EBV. Recently the presence ofclonal
episomal EBV in the Reed-Sternberg cells
has been demonstrated in about half of
cases. In these cases, the latent viral protein
expression is the same as that seen in
nasopharyngeal carcinoma. It is presently
unknown whether the serologic and risk
factor data are internally consistent with
the molecular data and whether EBV-nega-
tive Hodgkin's disease has a different
etiology.
The relationship between genital HPV
strains and malignancy is much less clear.
Most research has focused on cervical can-
cer, where the epidemiologic evidence
points to the role of a sexually transmitted
infection. It is probable that HPV will
eventually be determined to play a role in a
range ofother malignancies. Much of this
lack of clarity probably reflects the unique
biology of these highly cell-associated
viruses, which have not been successfully
grown in tissue culture or been found to
elicit a notable antibody response (14).
Thus, currently the only strategy for
identification is to use molecular probes,
which requires tissue from both cases and
controls and raises issues related to test per-
formance (15). Recently, there has been
some success in developing antibody assays
(16). The accumulating data strongly sug-
gest that these oncogenic viruses are part of
the causal chain (17). Whether antiviral
intervention in high-risk women may be of
benefit is unknown. Since early infection
appears to be important, behavioral inter-
vention among young women and their
sexual partners is likely to be protective.
Finally, an important modifier of risk
for both EBV and HPV (and probably the
other oncogenic viruses) is HIV-1 infection
(18). This includes the high risk of non-
Hodgkin's lymphoma (both EBV positive
and negative), cervical cancer, and to a
lesser extent, Hodgkin's disease as oppor-
tunistic malignancies. These observations
emphasize the importance ofimmune con-
trol ofthese generally prevalent infections.
Thus, primary prevention for HIV-1 infec-
tion, either through changes in sexual
behavior or by vaccination, will also reduce
the burden ofvirus-associated malignancy.
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